J Appl Biomed 19:73-82, 2021 | DOI: 10.32725/jab.2021.002
Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA
- 1 São Paulo State University - UNESP, Institute of Biosciences of Botucatu, Department of Microbiology and Immunology, Botucatu, São Paulo State, Brazil
- 2 Specialist Outpatient Service for Infectious Diseases "Domingos Alves Meira" (SAEI-DAM), Botucatu, São Paulo State, Brazil
- 3 São Paulo State University - UNESP, Botucatu Medical School, Department of Tropical Diseases and Imaging Diagnosis, Botucatu, São Paulo State, Brazil
Background: Despite the many benefits that follow antiretroviral therapy (ART) initiation, its chronic use contributes to the early aging of people living with HIV/AIDS (PLWHA). The aim of this cross-sectional study was to trace the prevalence of and investigate possible renal, bone and metabolic changes, as well as cardiovascular risk in 94 asymptomatic PLWHA, relating them to the duration of ART use.
Methods: Four groups were evaluated according to ART use: G1 (n = 21), ART-naïve individuals; G2 (n = 17), <2 years; G3 (n = 40), 2-10 years; and G4 (n = 16) on ART for more than 10 years.
Results: Our results showed a high prevalence of dyslipidemic individuals (64%), especially in those under ART. Lower creatine phosphokinase levels were observed in G1 as compared to the others (p < 0.05). Regarding the Framingham score, 12.1% of PLWHA showed moderate and high risk, and the highest proportion (38.5%) occurred in G4 (p = 0.003). A decrease in glomerular filtration rates occurred in 20% of patients, which was also more significant in G3 and G4 (p = 0.007). High prevalences of osteopenia and osteoporosis (53.2%) were found, especially in G1 and G4; however, G1 showed the lowest means for alkaline phosphatases (AP, p = 0.04 and BAP, p = 0.005) and osteocalcin (p = 0.005), in addition to higher vitamin-D concentrations (p = 0.04).
Conclusions: Our study showed the possible contributory role of ART in these changes, which leads us to reflect on the need for specific conducts and patient care, pointing out the importance of individualized care in an attempt to increase life expectancy.
Keywords: Antiretroviral; Dyslipidemia; HIV, Aids; Non-AIDS comorbidities
Grants and funding:
São Paulo Research Foundation, Brazil (FAPESP, Proc. 2016/15440- 4) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Conflicts of interest:
The authors declare that they have no conflicts of interest.
Received: April 27, 2020; Revised: December 22, 2020; Accepted: January 21, 2021; Prepublished online: January 27, 2021; Published: March 3, 2021 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
Attachments
Download file | JAB_Tasca_1309_002_annex.pdf File size: 32.06 kB |
References
- Balloca F, D'Ascenzo F, Gili S, Grosso Marra W, Gaita F (2017). Cardiovascular disease in patients with HIV. Trends Cardiovasc Med 27(8): 558-563. DOI: 10.1016/j.tcm.2017.06.005.
Go to original source...
Go to PubMed...
- Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004). Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 72 subjects. Eur J Clin Microbiol Infect Dis 23(8): 625-30. DOI: 10.1007/s10096-004-1177-6.
Go to original source...
Go to PubMed...
- Bestawros M, Chidumayo T, Blevins M, Canipe A, Bala J, Kelly P, et al. (2015). Increased systemic inflammation is associated with cardiac and vascular dysfunction over the first 12 weeks of antiretroviral therapy among undernourished, HIV-infected adults in Southern Africa. J AIDS Clin Res 6(3): 431. DOI: 10.4172/2155-6113.1000431.
Go to original source...
Go to PubMed...
- Bijker R, Jiamsakul A, Uy E, Kumarasamy N, Ditango R, Chaiwarith R, et al. (2019). Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 20(3): 183-191. DOI: 10.1111/hiv.12687.
Go to original source...
Go to PubMed...
- Bolland M, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. (2006). Bone Mineral Density is not reduced in HIV infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 65(2): 191-197. DOI: 10.1111/j.1365-2265.2006.02572.x.
Go to original source...
Go to PubMed...
- Bolland M, Grey A, Reid IR (2015). Skeletal health in adults with HIV infection. Lancet Diabetes Endocrinol 3(1): 63-74. DOI: 10.1016/S2213-8587(13)70181-5.
Go to original source...
Go to PubMed...
- Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. (2010). High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24(18): 2827-2833. DOI: 10.1097/QAD.0b013e328340a28d.
Go to original source...
Go to PubMed...
- Bonnet E, Ruidavets JB, Genoux A, Mabile L, Busato F, Obadia M, et al. (2013). Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study. BMC Infect Dis 13:293. DOI: 10.1186/1471-2334-13-293.
Go to original source...
Go to PubMed...
- Bonotto EH, Guerchon G, Coelho PHL, Ribeiro CE, do Nascimento MM (2016). Prevalence of chronic kidney disease in HIV-positive patients followed up at the HC-UHPR. Rer Med UFPR 4(4): 167-172. DOI: 10.5380/rmu.v4i4.50646.
Go to original source...
- Brasil. Ministério da Saúde (2008). Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV 2007/2008. Documento preliminar. [online] [cit. 2020-11-07]. Available from: https://www.who.int/hiv/amds/consenso_2008_brasil.pdf
- Brasil, Ministério da Saúde (2018). Departamento de Vigilância, Prevenção e controle das IST, HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da
- Infecção pelo HIV em Adultos. [online] [cit. 2020-11-07]. Available from: http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
- Brasil, Ministério da Saúde (2019). Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Boletim epidemiológico de HIV e Aids. [online] [cit. 2020-11-07]. Available from: https://antigo.saude.gov.br/images/pdf/2019/novembro/29/Boletim-Ist-Aids-2019-especial-web.pdf
- Brown TT, McComsey GA (2010). Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 15(3): 425-429. DOI: 10.3851/IMP1502.
Go to original source...
Go to PubMed...
- Brown TT, Qaqish RB (2006). Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17): 2165-2174. DOI: 10.1097/QAD.0b013e32801022eb.
Go to original source...
Go to PubMed...
- Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA (2009). Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 51(5): 554-561. DOI: 10.1097/QAI.0b013e3181adce44.
Go to original source...
Go to PubMed...
- Cristelli MP, Trullàs JC, Cofán F, Rico N, Manzardo C, Ambrosioni J, et al. (2018). Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. Braz J Infect Dis 22(3): 193-201. DOI: 10.1016/j.bjid.2018.05.001.
Go to original source...
Go to PubMed...
- Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S, Barahona I, Brodine S (2010). Prevalence and factors associated with renal dysfunction among HIV Infected patients. AIDS Patient Care STDS 24(6): 353-360. DOI: 10.1089/apc.2009.0326.
Go to original source...
Go to PubMed...
- d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, et al. (2019). Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. HIV Med 20(2): 99-109. DOI: 10.1111/hiv.12683.
Go to original source...
Go to PubMed...
- Dai L, Liu A, Zhang H, Wu H, Zhang T, Su B, et al. (2019). Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Curr HIV Res 17(5): 324. DOI: 10.2174/1570162X17666191025115508.
Go to original source...
Go to PubMed...
- Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. (2011). Low vitamin D among HIV-Infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in US general population. Clin Infect Dis 52(3): 396-405. DOI: 10.1093/cid/ciq158.
Go to original source...
Go to PubMed...
- Deeks S (2011). HIV Infection, Inflammation, Immunosenescence, and Aging. Ann Rev Med 62: 141-155. DOI: 10.1146/annurev-med-042909-093756.
Go to original source...
Go to PubMed...
- Déti EK, Thiébaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, et al. (2010). Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 11(5): 308-317. DOI: 10.1111/j.1468-1293.2009.00780.x.
Go to original source...
Go to PubMed...
- Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL (2018). Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents 52(5): 541-553. DOI: 10.1016/j.ijantimicag.2018.07.010.
Go to original source...
Go to PubMed...
- Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, et al. (2009). Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 207(2): 524-529. DOI: 10.1016/j.atherosclerosis.2009.05.001.
Go to original source...
Go to PubMed...
- Egger M, Junghans C, Friis-Møller N, Lundgren JD (2001). Highly active antiretroviral therapy and coronary heart disease: the need for perspective. Aids 15: S193-S201. DOI: 10.1097/00002030-200100005-00023.
Go to original source...
Go to PubMed...
- Faludi AA, de Oliveira Izar MC, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A, et al. (2017). Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose - 2017. Arq Bras Cardiol 109(2 Suppl. 1): 1-76. DOI: 10.5935/abc.20170121.
Go to original source...
Go to PubMed...
- Francisci D, Pirro FM, Schiaroli E, Mannarino MR, Cipriani S, Bianconi V, et al. (2019). Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study. Open Forum Infect Dis 6(4): ofz112. DOI: 10.1093/ofid/ofz112.
Go to original source...
Go to PubMed...
- Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349(21): 1993-2003. DOI: 10.1056/NEJMoa030218.
Go to original source...
Go to PubMed...
- Fukumoto AECG, Oliveira CC, Tasca KI, Souza LR (2013). Evolution of patients with aids after cART: clinical and laboratory evolution of patients with aids after 48 weeks of antiretroviral treatment. Rev Inst Med trop S. Paulo 55(4): 267-273. DOI: 10.1590/S0036-46652013000400008.
Go to original source...
- Gallant JE, Staszewski S, PozniK AL, DeJesus E, Suleiman JMAH, Miller MD, et al. (2004). Eficacy and safety of tenofovir DF VS stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2): 191-201. DOI: 10.1001/jama.292.2.191.
Go to original source...
Go to PubMed...
- Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. (2011). Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53(11): 1120-1126. DOI: 10.1093/cid/cir627.
Go to original source...
Go to PubMed...
- Hajjar LA, Calderaro D, Yu PCh, Giuliano I, de Oliveira Lima EM, et al. (2005). Cardiovascular manifestations in patients infected with the human immunodeficiency virus. Arq Bras Cardiol 85(5): 363-377. DOI: 10.1590/S0066-782X2005001800013.
Go to original source...
Go to PubMed...
- Harris VW, Brown TT (2012). Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205(Suppl. 3): S391-398. DOI: 10.1093/infdis/jis199.
Go to original source...
Go to PubMed...
- Hidalgo JA, Florez A, Agurto C, Pinedo Y, Ayarza R, Rodriguez L, et al. (2018). Metabolic and Cardiovascular Comorbidities Among Clinically Stable HIV Patients on Long-Term ARV Therapy in Five Ambulatory Clinics in Lima-Callao, Peru. Open AIDS J 12: 126-135. DOI: 10.2174/1874613601812010126.
Go to original source...
Go to PubMed...
- Hirakawa H, Gatanaga H, Ochi H, Fukuda T, Sunamura S, Oka S, et al. (2017). Antiretroviral Therapy Containing HIV Protease Inhibitors Enhances Fracture Risk by Impairing Osteoblast Differentiation and Bone Quality. J Infect Dis 215(12): 1893-1897. DOI: 10.1093/infdis/jix246.
Go to original source...
Go to PubMed...
- Kanis JA, on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary healthcare level. Technical Report. Sheffield, UK: WHO Collaborating Centre. [online] [cit. 2017-03-01]. Available from: https://www.shef.ac.uk/FRAX/tool.aspx?country=55
- Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, 3rd, Khaltaev N (2008). A reference standard for the description of osteoporosis. Bone 42(3): 467-475. DOI: 10.1016/j.bone.2007.11.001.
Go to original source...
Go to PubMed...
- Krikke M, Tesselaar K, van den Berk GEL, Otto SA, Freriks LH, van Lelyveld SFL, et al. (2018). The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients. HIV Clin Trials 19(2): 75-83. DOI: 10.1080/15284336.2018.1455366.
Go to original source...
Go to PubMed...
- Kwak MK, Lee EJ, Park JW, Park SY, Kim B-J, Kin TH, et al. (2019). CD4 T cell count is iversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years. Osteoporos Int 30(7): 1501-1510. DOI: 10.1007/s00198-019-04942-7.
Go to original source...
Go to PubMed...
- Lugon JR (2009). Chronic Kidney Disease in Brazil: A Public Health Problem. J Bras Nefrol 31: 2-5.
- Madeddu G, De Socio GVL, Ricci E, Quirino T, Orofino G, Carenzi L, et al. (2015a). Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance. Int J Anticrob Agents 45(3): 289-294. DOI: 10.1016/j.ijantimicag.2014.10.01.
Go to original source...
- Madeddu G, Spanu A, Solinas P, Babudieri S, Calia GM, Lovigu C, et al. (2015b). Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients. Eur Rev Med Pharmacol Sci 19(23): 4576-4589.
Go to PubMed...
- Menezes AM, Torelly J, Jr., Real L, Bay M, Poeta J, Sprinz E (2011). Prevalence and Risk Factors Associated to Chronic Kidney Disease in HIV-Infected Patients on HAART and Undetectable ViralLoad in Brazil. PLoS ONE 6(10): e26042. DOI: 10.1371/journal.pone.0026042.
Go to original source...
Go to PubMed...
- Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, Chilongola J (2012). The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afr Health Sci 12(1): 2-7.
Go to PubMed...
- Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. (2007). Chronic renal failure among HIV-1-infected patients. AIDS 21(9): 1119-1127. DOI: 10.1097/QAD.0b013e3280f774ee.
Go to original source...
Go to PubMed...
- National Kidney Foundation (2011). Frequent asked questions about GFR estimates. [online] [cit. 2019-05-02]. Available from: http://www.kidney.org/professionals/kls/pdf/12-10-4004_KBB_FAQs_AboutGFR-1.pdf
- Neaton JD, Neuhaus J, Emery S (2010). Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV Aids 5(6): 480-490. DOI: 10.1097/COH.0b013e32833ed75d.
Go to original source...
Go to PubMed...
- Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, et al. (2016). Antiretrovieal therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 30: 405-414. DOI: 10.1097/QAD.0000000000000918.
Go to original source...
Go to PubMed...
- Palella FJ, Jr., Phair JP (2011). Cardiovascular disease in HIV infection. Curr Opin HIV/AIDS 6(4): 266-271. DOI: 10.1097/COH.0b013e328347876c.
Go to original source...
Go to PubMed...
- Pinto Neto LF da S, das Neves MB, Ribeiro-Rodrigues R, Page K, Miranda AE (2013). Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz J Infect Dis 17(4): 438-443. DOI: 10.1016/j.bjid.2012.12.006.
Go to original source...
Go to PubMed...
- Pinto Neto LF da S, Ragi-Eis S, Vieira NFR, Soprani M, Neves MB, Ribeiro-Rodrigues R, Miranda AE (2011). Low bone mass prevalence, therapy type, and clinical risk factors in an HIV-infected Brazilian population. J Clin Densitom 14(4): 434-439. DOI: 10.1016/j.jocd.2011.06.004.
Go to original source...
Go to PubMed...
- Ramana KV, Rao R, Kandi S, Singh PA, Kumar VBP (2013). Elevated activities of serum lactate dehydrogenase in human immunodeficiency virus sero-positive patients in highly active antiretroviral therapy era. 2(3): 162-166. DOI: 10.4103/2277-8632.117180.
Go to original source...
- Shiau S, Broun EC, Arpadi SM, Yin MT (2013). Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS 27(12): 1949-1957. DOI: 10.1097/QAD.0b013e328361d241.
Go to original source...
Go to PubMed...
- Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. (2014). Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384(9939): 241-248. DOI: 10.1016/S0140-6736(14)60604-8.
Go to original source...
Go to PubMed...
- Souza SJ, Luzia LA, Santos SS, Rondó PHC (2013). Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras 59(2): 186-198. DOI: 10.1016/j.ramb.2012.11.003.
Go to original source...
Go to PubMed...
- Stellbrink H-J, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Vijngaerden E, et al. (2010). Comparison of changes in Bone Density and turnover with abacavir-lamivudine versus tenofovir-entricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51(8): 963-972. DOI: 10.1086/656417.
Go to original source...
Go to PubMed...
- Suligoi B, Virdone S, Taborelli M, Frova L, Grande E, Grippo F, et al. (2018). Excess mortality related to circulatory system diseases and diabetes mellitus among Italian AIDS patients vs. non-AIDS population: a population-based cohort study using the multiple causes-of-death approach. BMC Infect Dis 18(1): 428. DOI: 10.1186/s12879-018-3336-x.
Go to original source...
Go to PubMed...
- Tasca KI, Caleffi JT, Correa CR, Gatto M, de Camargo CC, Mendes MB, et al. (2016). The Initial Months of Antiretroviral Therapy and Its Influence on AGEs, HMGB1, and sRAGE Levels in Asymptomatic HIV-Infected Individuals. Mediators Inflamm 2016: 2909576. DOI: 10.1155/2016/2909576.
Go to original source...
Go to PubMed...
- Triant VA (2013). Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep 10(3): 199-206. DOI: 10.1007/s11904-013- 0168-6.
Go to original source...
Go to PubMed...
- UNAIDS - Joint United Nations Programme on HIV/AIDS (2015). Fast-Track: accelerating action to end the AIDS epidemic by 2030. [online] [cit. 2019-25-22]. Avaliable from:
- Vlot MC, Grijsen ML, Prins JM, de Jongh RT, de Jonge R, den Heijer M, Heijboer AC (2018). Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. PLoS One 13(3): e0193679. DOI: 10.1371/journal.pone.0193679.
Go to original source...
Go to PubMed...
- Vos AG, Chersich MF, Klipstein-Grobusch K, Zuithoff P, Moorhouse MA, Lalla-Edward ST, et al. (2018). Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir. Retrovirology 15(1): 77. DOI: 10.1186/s12977-018-0460-z.
Go to original source...
Go to PubMed...
- Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, et al. (2007). Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21(18): 2445-2453. DOI: 10.1097/QAD.0b013e3282efad32.
Go to original source...
Go to PubMed...
- Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz B, Kannel WB (1998). Prediction of coronary heart disease using risk factor categories. Circulation 97: 1937-1947. DOI: 10.1161/01.CIR.97.18.1837.
Go to original source...
Go to PubMed...
- Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, et al. (2014). Change in vitamin D levels and risk of sever vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naïve adults receiving rilpivirine or efavirenz in a phase III trial (ECHO). Antivir Ther 19: 191-200. DOI: 10.3851/IMP2721.
Go to original source...
Go to PubMed...
- Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201(3): 318-330. DOI: 10.1086/649897.
Go to original source...
Go to PubMed...
- Yin MT, Falutz J (2016). How to predict risk of fracture in HIV? Curr Opin HIV AIDS 11(3): 261-267. DOI: 10.1097/COH.0000000000000273.
Go to original source...
Go to PubMed...
- Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, et al. (2005). Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study. Antiv Ther 10(5): 585-591.
Go to original source...
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.